*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2026 | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians The American journal of sports medicine · preclinical | PMID 41476424 |
| 2024 | The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism Physiology & behavior · preclinical | PMID 39043357 |
| 2020 | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males Translational andrology and urology · preclinical | PMID 32257855 |
| 2020 | Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics Journal of experimental pharmacology · preclinical | PMID 32801950 |
| 2018 | Analysis of new growth promoting black market products Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · preclinical | PMID 29864719 |
| 2012 | Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus Journal of experimental pharmacology · preclinical | PMID 27186127 |
| 2009 | Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus The Journal of pharmacology and experimental therapeutics · preclinical | PMID 19289567 |
| 2009 | Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · preclinical | PMID 19231263 |
| 2002 | Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro Histology and histopathology · preclinical | PMID 12168778 |
| 2001 | The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · preclinical | PMID 11735244 |
| 1999 | Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · preclinical | PMID 10373343 |
| 1999 | Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Pharmaceutical research · human | PMID 10496658 |
| 1998 | Ipamorelin, the first selective growth hormone secretagogue European journal of endocrinology · preclinical | PMID 9849822 |
| 1998 | Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption Xenobiotica; the fate of foreign compounds in biological systems · preclinical | PMID 9879640 |
Ipamorelin (Ipamorelin (selective GH secretagogue)). Selective ghrelin-receptor (GHS-R) agonist / growth-hormone secretagogue. Stimulates pulsatile GH release with minimal effect on cortisol, prolactin, or appetite vs older GHRPs.
Commonly discussed uses: GH axis support (research), recovery/sleep (anecdotal), body composition. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Selective ghrelin-receptor (GHS-R) agonist / growth-hormone secretagogue. Stimulates pulsatile GH release with minimal effect on cortisol, prolactin, or appetite vs older GHRPs.
Reported considerations: anecdotal: head-rush, flushing, mild headache, injection-site reaction. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg, typical 200-300mcg per dose, 1-3x/day, high 300mcg 3x/day. Administration: subcutaneous. Half-life: ~2 hours.
Australian status: Not ARTG-registered; prescription/research. WADA-prohibited. Not approved for human therapeutic use. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5mg vial; storage: reconstituted refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): Ipamorelin + CJC-1295 (GH-axis stack). Stacking increases interaction/safety uncertainty.